Relevium Technologies Inc. (TSXV:RLV, OTCQB:RLLVF, Frankfurt:6BX) (the “Company” or “Relevium”), is pleased to announce the appointment of Mark Billings, CFA as Chief Financial Officer for both Relevium and Biocannabix Health Corporation effective immediately. Mr. Billings replaces Faycal Salek who has resigned to pursue other opportunities.
Mr. Billings is an experienced executive Chartered Financial Analyst and a graduate of the Harvard School of Business. Mr. Billings has founded and managed companies in the junior resource sector, where he acted as CEO, CFO and board member. Mr. Billings serves on the board of several publicly traded resource companies in Canada and abroad. In addition to his executive career, Mr. Billings has been an investment banker, having raised hundreds of millions of dollars for small-cap companies, including several junior mining companies.
Aurelio Useche, CEO of Relevium stated: “Mr. Billings is a veteran in the public markets and brings to our company extensive experience in capital markets, M&A transactions and overall financial acumen, all of which are necessary for the next stage of the development of our business. We look forward to his active participation in the strategic planning process, development and execution of the company’s objectives”
Mr. Useche continued: “On behalf of the entire board and management team, we would like to thank Mr. Faycal Salek for his valuable contributions and wish him success in his new endeavors.”
About Relevium Technologies
Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.
Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy. The Company has an international ecosystem and footprint that ensures vertical integration from phyto-genetics through clinical validation and eventual commercialization of its products.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.